Wall Street closes at a record for the first time since end of January
ROCKAWAY, N.J. - electroCore, Inc. (NASDAQ:ECOR) announced the publication of clinical findings in Frontiers in Neuroscience examining non-invasive vagus nerve stimulation for patients with chronic mild traumatic brain injury and post-traumatic stress disorder.
The publication reports a post-hoc analysis of 35 patients with chronic mild traumatic brain injury and comorbid PTSD. The analysis indicated that adjunctive non-invasive vagus nerve stimulation reduced overall symptom burden, with improvements observed across cognitive, affective, and somatic domains, according to the press release statement.
The study was authored by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard. The study population represented a high-symptom-burden cohort associated with persistent neurobehavioral symptoms.
"Mild TBI can have lasting neurobehavioral consequences," said Dr. Peter Staats, Chief Medical Officer of electroCore. "This data suggests that adjunctive vagus nerve stimulation may provide meaningful clinical benefit in this complex patient population and adds significantly to the literature on the use of vagus nerve stimulation in patients with PTSD."
electroCore is a bioelectronic technology company that develops non-invasive bioelectronic technologies. The company’s prescription products include gammaCore non-invasive vagus nerve stimulation for certain primary headache conditions and Quell Fibromyalgia for fibromyalgia symptom reduction. The company also commercializes Truvaga and TAC-STIM products for general wellness applications.The company, with a market cap of $48.7 million, has demonstrated strong commercial momentum with revenue growth of 27% over the last twelve months and impressive gross profit margins of 87%. The stock has surged 34% year-to-date, though InvestingPro analysis suggests the shares are currently trading above their Fair Value. For deeper insights into electroCore’s financial health and growth prospects, investors can access comprehensive analysis through the company’s Pro Research Report, available for this and 1,400+ other US equities.
The findings were published today in the peer-reviewed journal Frontiers in Neuroscience. Analysts remain bullish on electroCore’s prospects, with price targets ranging from $12 to $25, well above the current trading price of $6.03.
In other recent news, electroCore, Inc. reported its earnings for the fourth quarter of 2025, highlighting significant revenue growth and enhanced operational efficiency. Despite this, the company experienced a widening net loss and increased operating expenses. The gross margin improved to 87%, indicating a favorable product mix and operational leverage. Additionally, electroCore announced the issuance of two U.S. patents for its non-invasive vagus nerve stimulation technology, which covers methods and systems for nerve modulation and therapy optimization. H.C. Wainwright maintained a Buy rating on electroCore’s shares, setting a price target of $18.00. This rating follows the company’s announcement of executive team changes, including the planned retirement of CEO Dan Goldberger in 2026. Under Goldberger’s leadership, the company saw its total revenues grow to $32 million in fiscal 2025 from $3.5 million in 2020. These developments reflect electroCore’s ongoing efforts to innovate and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.